While Middletown, Delaware’s main claim to fame was the site location for the film the Dead Poets Society, the city will soon play host to a massive manufacturing outfit.
WuXi AppTec’s contract research and manufacturing subsidiary WuXi STA, has broken ground on a 190-acre manufacturing campus in Middletown.
According to the company, this site will be WuXi’s second facility in the US, and it will create around 500 full-time jobs by 2026, but there are plans to kick off operations in 2025.
A report from the Delaware BioScience Association said WuXi paid $30 million for the land with the site costing a total of $510 million. The site is also backed by $19 million in taxpayer-funded grants.
The company states that this is the first phase of the new campus. While it did not provide information on what exact products will be manufactured once completed, the site will be able to provide formulation development and clinical and commercial drug product manufacturing services for oral and injectable products. The site will also be able to package, label, store and distribute services for clinical trial materials and commercial drug products.
“WuXi STA continues to increase our capabilities and capacities to better serve our customers through a more robust and reliable supply chain. With our integrated Contract Research, Development, and Manufacturing Organization (CRDMO) platform and proven quality system, we look forward to working with our customers to swiftly deliver their innovative therapies to market in order to save lives and improve healthcare for patients,” said WuXi CEO Minzhang Chen in a statement.
The company said in an email to Endpoints News that Delaware was chosen because the state has a growing healthcare industry as well as a highly trained pharma manufacturing workforce.
While the company also did not go into details about any future building phases, when the site was announced in 2021, the company said the site could expand to hire more than 1,000 employees, with 600,000 square feet of space in at least three buildings, including one for drugs, one for administration, and one for drug substances.
While WuXi finds itself in good company with companies such as AstraZeneca and Charles River in Delaware, the company has been looking to expand rapidly across the globe.
This year the company has opened an HPAPI plant at its Changzhou site in Jiangsu, China, and two large-scale oligonucleotide and peptide manufacturing facilities at its campus in Changzhou, China. Last year the company acquired Bristol Myers Squibb’s site in Couvet, Switzerland, which specializes in commercial-scale production of various capsules and tablet dosage forms.